U.S. Markets close in 4 hrs 8 mins

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.7143-0.0491 (-6.43%)
As of 11:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7634
Bid0.7125 x 1200
Ask0.7156 x 900
Day's Range0.7080 - 0.7599
52 Week Range0.6000 - 4.4600
Avg. Volume2,664,243
Market Cap34.273M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.6620
Earnings DateOct 21, 2020 - Oct 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.60
  • Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

    Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

    Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Acorda Therapeutics: Q2 Earnings Insights

    Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 20% after the company reported Q2 results.Quarterly Results Earnings per share rose 36.36% year over year to ($0.35), which beat the estimate of ($0.48).Revenue of $33,617,000 decreased by 32.84% from the same period last year, which beat the estimate of $27,500,000.Outlook Earnings guidance hasn't been issued by the company for now.Acorda Therapeutics hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 04, 2020View more earnings on ACORTime: 04:30 PMET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fpro.benzinga.com%2Fdashboard%2F&eventid=2395726&sessionid=1&key=EF22DB54EC8EDBD04D72B50A619971E1®Tag=&sourcepage=registerPrice Action 52-week high: $5.5652-week low: $0.60Price action over last quarter: down 24.40%Company Profile Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.See more from Benzinga * Stocks That Hit 52-Week Lows On Thursday * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session * Stocks That Hit 52-Week Lows On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Acorda Reports Second Quarter 2020 Financial Results
    Business Wire

    Acorda Reports Second Quarter 2020 Financial Results

    Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2020.